This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsLet’s ConnectStock Hub

Menu

Close

EfficacyEfficacyKey HighlightsEfficacyHospitalisation DataSafetySafetySafetyAdverse Event Management: VOD/SOSKey PrecautionsDosingDosingDosingAdministrationSupport and ResourcesSupport and ResourcesSupport and ResourcesGuidelinesFast FactsPharmacy GuidePatient SupportDevelopments in Leukaemia Care videoKey data from the INO-VATE study videoManagement of Refractory/Relapsed ALL videoMRD PubExplainer videoINO-VATE PubExplainer videoVideosMaterials

The content of this website has been produced in line with the BESPONSA® (inotuzumab ozogamicin) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BESPONSA Prescribing Information for Great Britain click here. BESPONSA Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.

Access the Guidelines NICE Recommended1:

BESPONSA (inotuzumab oxogamicin) is recommended as an option for treating relapsed or refractory CD22-positive B-call precursor acute lymphoblastic leukaemia in adults. People with relapsed or refractory Philadelphia chromosome positive disease should have had at least 1 tyrosine kinase inhibitor (TKI).

Learn more Loading
Scottish Medicine Consortium (SMC)2

Advice: following a full submission assessed under the ultra-orphan and end of life medicine process: ​​​​​​​

Inotuzumab ozogamicin (BESPONSA) is accepted for restricted use within NHS Scotland.

Indication under review: as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive relapsed or refractory B cell precursor ALL should have failed treatment with at least one tyrosine kinase inhibitor.

SMC restriction: in patients for whom the intent is to proceed to stem cell transplantation.

A phase III open label randomised controlled study demonstrated improvements in remission rates and overall survival for the patient population under review when treated with inotuzumab ozogamicin compared with standard chemotherapy.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of inotuzumab ozogamicin. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting

Learn more Loading
Explore more
Developments in Leukaemia Care

Watch Professor David Marks discuss targeted therapies and the INO-VATE study, including 3 year follow up and impact of allogeneic bone marrow transplantation on survival

Learn MoreLoading
Management of Refractory/Relapsed ALL 

Hear Professor David Marks discuss the INO-VATE study including MRD negativity, long term survival and reducing risks of veno-occlusive disease

Learn More Loading

NICE, National Institute for Health and Care Excellence; SMC, Scottish Medicines Consortium

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

Reference

NICE Technology Appraisal Guidance (TA541). Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia. Available at: https://www.nice.org.uk/guidance/TA541 Published: 19 September 2018. [accessed January 2022].Scottish Medicines Consortium. Inotuzumab ozogamicin (BESPONSA): 1328/18 (Published: 11 June 2018). Available at: https://www.scottishmedicines.org.uk/medicines-advice/inotuzumab-ozogamicin-besponsa-fullsubmission-132818/ [accessed January 2022].​​​​​​​
PP-INO-GBR-0625. February 2022
Quick links
Fast Facts

Download the Fast Facts Guide holding the key information for BESPONSA including mode of action, INO-VATE study design, INO-VATE results; efficacy and safety profile. Summary of Product Characteristics (SmPC) should be consulted for full guidance.

Download here Loading

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc


This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


Copyright © 2021 Pfizer Limited. All rights reserved.


VAT registration number GB201048427

PP-UNP-GBR-0596. April 2022

Add indication message here. It can link a link,
and you can EMBOLDEN text

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?

You are now leaving PfizerPro
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

​​​​​​​Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes No
You are now leaving PfizerPro
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​